Scholarlink

<p>Venous thromboembolism (VTE) remains a major contributor to postoperative morbidity and mortality in patients undergoing lung cancer surgery. This study aims to identify perioperative risk factors associated with VTE development following such procedures. We performed an exhaustive search of PUBMED and EMBASE from inception to November 1, 2023, using terms related to VTE following lung cancer surgery. A random-effects meta-analysis was performed to calculate the pooled incidence and odds ratios (ORs) for risk factors. Of 3,576 screened studies, 13 met eligibility criteria for qualitative synthesis, and 11 studies (53,382 patients) were included in the meta-analysis. The pooled incidence of postoperative VTE was 1.82% (971 cases). Significant risk factors included advanced age (standardized mean difference [SMD] 0.43, 95% CI 0.22–0.63; I<sup>2</sup> = 59.9%), prolonged surgical duration (SMD 0.58, 95% CI 0.24–0.92; I<sup>2</sup> = 81.2%), open thoracotomy (OR 1.77, 95% CI 1.50–2.09; I<sup>2</sup> = 19.9%), TNM stage &gt; 1 (OR = 1.81, 95% CI 1.53–2.13; I<sup>2</sup> = 39.8%), adenocarcinoma histology (OR = 1.29, 95% CI 1.08–1.53; I<sup>2</sup> = 1.2%), and major lung resection (OR = 1.51, 95% CI 1.24–1.83; I2 = 0.0%). This study highlights key modifiable and non-modifiable risk factors for postoperative VTE in lung cancer surgery patients. These findings support individualized risk stratification and targeted thromboprophylaxis strategies to improve clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Postoperative venous thromboembolism risk following lung cancer surgery: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月8日

查看全文
  • Jing Chen,
  • Yuanzheng Mao,
  • Zhiyu Peng

摘要

Venous thromboembolism (VTE) remains a major contributor to postoperative morbidity and mortality in patients undergoing lung cancer surgery. This study aims to identify perioperative risk factors associated with VTE development following such procedures. We performed an exhaustive search of PUBMED and EMBASE from inception to November 1, 2023, using terms related to VTE following lung cancer surgery. A random-effects meta-analysis was performed to calculate the pooled incidence and odds ratios (ORs) for risk factors. Of 3,576 screened studies, 13 met eligibility criteria for qualitative synthesis, and 11 studies (53,382 patients) were included in the meta-analysis. The pooled incidence of postoperative VTE was 1.82% (971 cases). Significant risk factors included advanced age (standardized mean difference [SMD] 0.43, 95% CI 0.22–0.63; I2 = 59.9%), prolonged surgical duration (SMD 0.58, 95% CI 0.24–0.92; I2 = 81.2%), open thoracotomy (OR 1.77, 95% CI 1.50–2.09; I2 = 19.9%), TNM stage > 1 (OR = 1.81, 95% CI 1.53–2.13; I2 = 39.8%), adenocarcinoma histology (OR = 1.29, 95% CI 1.08–1.53; I2 = 1.2%), and major lung resection (OR = 1.51, 95% CI 1.24–1.83; I2 = 0.0%). This study highlights key modifiable and non-modifiable risk factors for postoperative VTE in lung cancer surgery patients. These findings support individualized risk stratification and targeted thromboprophylaxis strategies to improve clinical outcomes.